Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented treatment benefits being obtained for cancer patients, including improved patient survival. However, over half of the patients experience immune related adverse events (irAEs) or toxicities, which can be fatal, aff...
Main Authors: | John Taylor, Aesha Gandhi, Elin Gray, Pauline Zaenker |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.991433/full |
Similar Items
-
Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events
by: Leonie Müller-Jensen, et al.
Published: (2024-04-01) -
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
by: Iñigo Les, et al.
Published: (2021-01-01) -
Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors
by: N.C. Helderman, et al.
Published: (2023-03-01) -
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01) -
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)